Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Dividend Kings to Buy in 2026. CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA (lumateperone), when used alongside an antidepressant, delivered significantly higher remission rates in adults with major depressive disorder compared with placebo plus an antidepressant after six weeks. The company also said the b ...

Core Insights - Johnson & Johnson is presenting 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology, focusing on advancements in neuropsychiatry, particularly in major depressive disorder (MDD) and treatment-resistant depression (TRD) [1][2] Group 1: Research Presentations - Key presentations include analyses of CAPLYTA (lumateperone) for remission in MDD, metabolic profiles of seltorexant versus quetiapine XR in MDD with insomnia, and effects of SPRAVATO (esketamine) on anhedonia in TRD [3][4] - Specific posters will cover the efficacy of lumateperone in various demographic and clinical subgroups, as well as treatment-emergent adverse events in MDD patients [3][4] Group 2: Company Commitment - Johnson & Johnson emphasizes its commitment to addressing unmet needs in depression, schizophrenia, and bipolar disorder, aiming for disease remission through innovative research and clinical findings [2] - The company is advancing its portfolio with a focus on novel mechanisms and AI-driven precision tools to redefine standards of care in neuropsychiatry [2] Group 3: Major Depressive Disorder (MDD) Insights - MDD affects approximately 332 million people globally, representing about 4% of the population, with around 22 million adults in the U.S. experiencing at least one major depressive episode in 2023 [6] - The disorder is complex and heterogeneous, with responses to treatment varying widely, highlighting the need for personalized approaches [6][7] - Approximately 60% of MDD patients experience insomnia symptoms, which significantly impact their quality of life and increase the risk of depressive relapse [7] Group 4: Treatment-Resistant Depression (TRD) Insights - About one-third of adults with MDD are classified as having TRD, defined as inadequate response to two or more oral antidepressants [8] - TRD poses a significant economic burden and affects patients' lives severely, with a high percentage not achieving remission even after multiple treatment attempts [8]

Core Insights - Johnson & Johnson announced the FDA approval of CAPLYTA (lumateperone) as an adjunctive therapy for major depressive disorder (MDD) in adults, marking a significant addition to treatment options for patients experiencing residual symptoms despite current antidepressant therapies [1][2][8] Summary by Sections Approval and Indications - CAPLYTA is now approved for use alongside antidepressants for MDD, as well as for bipolar I and II depression and schizophrenia, making it the first FDA-approved treatment for bipolar depression in adults [1][15] - This approval follows Johnson & Johnson's acquisition of Intra-Cellular Therapies, Inc., and represents the fourth indication for CAPLYTA [1][8] Clinical Efficacy - The approval is based on positive results from two Phase 3 trials (Study 501 and 502), which demonstrated significant improvements in depression symptoms compared to placebo [2][12] - In Study 501, the mean change in Montgomery-Asberg Depression Rating Scale (MADRS) score was -4.9 points (effect size 0.61), while Study 502 showed a -4.5 points change (effect size 0.56) at six weeks [3][12] - Early separation from placebo was observed as soon as one week in Study 501 and two weeks in Study 502 [3] Safety and Tolerability - CAPLYTA's safety profile was consistent with previous studies, showing no new safety concerns, and weight gain and metabolic changes were similar to placebo [4][6] - The most common side effects included sleepiness, dizziness, nausea, dry mouth, fatigue, and diarrhea [4][22] - In a 26-week open-label extension study (Study 503), 80% of patients responded to treatment, and 65% achieved remission, defined as a MADRS total score of 10 or less [6][13] Mechanism of Action - While the exact mechanism of action is not fully understood, CAPLYTA is characterized by high serotonin 5-HT2A receptor occupancy and moderate dopamine D2 receptor occupancy at therapeutic doses [7][16] Market Context - MDD affects approximately 22 million adults in the U.S., with 2 in 3 patients experiencing residual symptoms despite treatment, highlighting the need for effective adjunctive therapies [1][11] - The introduction of CAPLYTA is expected to reset treatment expectations and provide hope for patients seeking remission from depression [5][8]

Core Insights - Johnson & Johnson presented 17 abstracts at the European College of Neuropsychopharmacology (ECNP) Congress, showcasing new clinical and real-world data on major depressive disorder (MDD) and treatment-resistant depression (TRD) [1][2]. Group 1: Major Depressive Disorder (MDD) - MDD affects approximately 332 million people globally, representing about 4% of the population, with around 22 million adults in the U.S. experiencing at least one major depressive episode in 2023 [8]. - The disorder is complex and heterogeneous, with up to 256 unique symptom combinations, leading to varied treatment responses [8]. - Current standard-of-care oral antidepressants leave 2 in 3 patients with residual symptoms, highlighting the need for innovative treatment approaches [8]. Group 2: Treatment-Resistant Depression (TRD) - About one-third of adults with MDD do not respond to oral antidepressants and are classified as having TRD, which significantly impacts their quality of life and has a high economic burden [11]. - The STAR*D study indicates that approximately 86% of patients do not achieve remission after trying their third oral antidepressant [11]. Group 3: New Treatment Data - New analyses from Phase 3 data evaluate the impact of CAPLYTA (lumateperone) on sexual function in MDD patients, suggesting a potential to reset treatment expectations [6]. - A sub-group analysis of Phase 3 data compares the efficacy of adjunctive seltorexant with quetiapine XR in MDD patients with insomnia symptoms [6]. - Findings from the ESCAPE-TRD study explore the association between patient characteristics and remission with SPRAVATO (esketamine) versus quetiapine XR in TRD patients [6]. Group 4: Company Commitment - Johnson & Johnson emphasizes a patient-first approach in developing innovative therapies for MDD and TRD, as stated by the Global Neuroscience Therapeutic Area Head [2].

Core Insights - Nuvectis Pharma, Inc. has appointed Dr. Juan Sanchez to its Board of Directors, bringing extensive experience in biotech and capital markets [1][3] - Dr. Sanchez previously served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, which was acquired by Johnson & Johnson for $14.6 billion in April 2025 [2][3] - The company is entering a new growth phase with the initiation of the Phase 1b program for its lead drug candidate, NXP900, aimed at treating advanced and treatment-resistant cancers [3][4] Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious unmet medical needs in oncology [4] - The lead program, NXP900, is an oral small molecule inhibitor targeting SRC Family of Kinases (SFK), having completed a Phase 1a dose escalation study and currently being evaluated in a Phase 1b program [4] - The company is also exploring next steps for NXP800, which has shown anti-cancer activity in specific ovarian cancer cases [4] Dr. Juan Sanchez's Background - Dr. Sanchez has over 30 years of experience in healthcare, combining roles in patient care, research analysis, and executive leadership in biopharmaceuticals [3] - His tenure at Intra-Cellular Therapies included the successful development and commercialization of CAPLYTA (lumateperone) [3] - Dr. Sanchez holds advanced degrees in International Affairs, Business Administration, and Medicine, and has practiced medicine for five years in Colombia [3]